This page has been optimized for print.

NeuroStar TMS Therapy® Recipient of Medical Design Excellence Award

Novel device for the treatment of depression named one of 2008's top medical device innovations

Malvern, PA, [April 21, 2009] /PRNewswire/ — NeuroStar® TMS (Transcranial Magnetic Stimulation) Therapy system, the first and only non-systemic and non-invasive treatment cleared by the FDA for Major Depressive Disorder, is a recipient of the prestigious Medical Design Excellence Award (MDEA). The award will be presented in June at the twelfth annual MD&DI (Medical Device & Diagnostic Industry) MDEA ceremony in New York City. Winners of the premier awards program for the medical technology community were announced in the April issue of MD&DI magazine. NeuroStar TMS Therapy was developed by Neuronetics Inc., a privately-held medical device company and a leader in the field of neuromodulation.

"We are pleased that our NeuroStar TMS Therapy system is a recipient of one of this year's Medical Design Excellence Awards. There are many people behind the scenes such as engineers, clinical staff, and designers who deserve this recognition. We are proud to have developed this innovative medical device to help the many people suffering with depression who are in need of a new treatment option," said Neuronetics' President and CEO, Bruce Shook.

NeuroStar TMS Therapy was cleared by the FDA in October 2008 for patients who have not adequately benefited from prior antidepressant medication.* NeuroStar TMS Therapy is a non-systemic (does not circulate in the bloodstream throughout the body) and non-invasive (does not involve surgery) form of neuromodulation. It stimulates nerve cells in an area of the brain that is linked to depression by delivering highly focused MRI-strength magnetic field pulses. The treatment is typically administered daily for four-six weeks.

In an open-label clinical trial, which is most like real world clinical practice, approximately one in two patients experienced significant improvement in symptoms, and one in three experienced complete symptom resolution. There were no systemic side effects, such as weight gain and sexual dysfunction. The most common adverse events related to treatment were scalp pain or discomfort at the treatment area during active treatments. NeuroStar TMS Therapy may not be effective for all patients with depression. NeuroStar TMS Therapy is currently available at over 25 treatment locations in 15 states (for details visit www.NeuroStarTMS.com).

About Neuronetics

Neuronetics, Inc. is a privately-held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. Based in Malvern, PA, Neuronetics is the leader in the development of TMS Therapy, a non-invasive form of neuromodulation. For more information, please visit www.neuronetics.com. For specific information on treatment locations with NeuroStar TMS Therapy, please visit www.NeuroStarTMS.com or call the Neuronetics Customer Service Center at (877) 600-7555.

About Depression

Depression affects at least 14 million American adults each year. Researchers estimate that by the year 2020, depression will be the second leading cause of disability worldwide. Each year, over 30,000 people in the U.S. commit suicide, 60 percent of which suffer from depression. The economic burden of depression in 2000 was estimated at $83.1 billion in the U.S. Women are almost twice as likely as men to suffer from depression. However, some experts feel that depression in men is under-reported. Depression has no racial, ethnic, or socioeconomic boundaries. About two-thirds of those who experience an episode of depression will have at least one other episode in their lives. Despite major advances in treating this debilitating illness, nearly 30 percent of patients with depression do not benefit from or are intolerant of antidepressant therapy.

Press Contacts:

Nancie Steinberg
Chamberlain Communications
Ph: 212-884-0667
Peter Anastasiou
Neuronetics, Inc.
Ph: 609-575-2780

* NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

NeuroStar®, NeuroStar TMS Therapy®, and TMS Therapy® are registered trademarks of Neuronetics, Inc.